Aspirin, Nonsteroidal Anti-inflammatory Drugs, Acetaminophen, and Pancreatic Cancer Risk
Cancer Prevention Research,
Tan XL et al. – The data suggest that aspirin use, but not non-aspirin nonsteroidal anti-inflammatory drugs (NSAID) use, is associated with lowered risk of developing pancreatic cancer
The authors used a clinic-based case-control study of 904 rapidly ascertained histologically or clinically documented pancreatic ductal adenocarcinoma cases, and 1,224 age- and sex-matched healthy controls evaluated at Mayo Clinic from April 2004 to September 2010.
Overall, there is no relationship between non-aspirin NSAID or acetaminophen use and risk of pancreatic cancer.
Aspirin use for 1d/mo or greater was associated with a significantly decreased risk of pancreatic cancer (OR=0.74, 95% CI: 0.60-0.91, P=0.005) compared with never or less than 1 d/mo.
Analysis by frequency and frequency-dosage of use categories showed reduced risk (P=0.007 and 0.022, respectively).
This inverse association was also found for those who took low-dose aspirin for heart disease prevention (OR=0.67, 95% CI: 0.49-0.92, P=0.013).
In subgroup analyses, the association between aspirin use and pancreatic cancer was not significantly affected by pancreatic cancer stage, smoking status, or body mass index.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.